@Article{biocell.2021.011379,
AUTHOR = {SHUCAI WU, DENGRUI LI, SUMIN GUO, LI GAO, YONGHUI YANG},
TITLE = {Different sources of MSCs on pulmonary fibrosis in C57BL/6 mice},
JOURNAL = {BIOCELL},
VOLUME = {45},
YEAR = {2021},
NUMBER = {2},
PAGES = {339--344},
URL = {http://www.techscience.com/biocell/v45n2/41547},
ISSN = {1667-5746},
ABSTRACT = {Since stem cell therapy is the most effective treatment in the field of tissue reparation and reconstitution, the
present study aimed to explore the different sources of mesenchymal stem cells (MSCs) on the different effects of
pulmonary fibrosis-related cytokines in C57BL/6 mice. For reaching this goal, we isolated MSCs from umbilical cord
blood and placenta and used for stem cell therapy in a mouse model of pulmonary fibrosis model. The pulmonary
fibrosis model was done by injecting bleomycin into the trachea of C57BL/6 mice. Then we assessed the degree of
pulmonary fibrosis in each mouse lung tissue at weeks 1, 2, 3, and 4. In addition, flow cytometry was used to evaluate
the frequency of CD73, CD90, CD106, CD34, CD45, CD14 cells at the mononuclear cell level; and western blotting
assays revealed the expression of IκB-α. Our results showed that stem cell therapy by placenta-derived MSC had a
lower level of CD34, CD45, CD14 cells at the mononuclear cell level, and that improved pulmonary fibrosis at both
molecular and pathological levels. In addition, western blotting assays revealed that the expression of IκB-α was
down-regulated in MSC-treated animals. In addition, placenta-derived MSC was the most effective in improving
pulmonary fibrosis in comparison to other sources. This study suggests that MSC might be a novel therapeutic
approach in pulmonary fibrosis due to an enhanced anti-inflammatory effect. Also, MSC modification by gene editing
could enhance their therapeutic effect in mouse pulmonary fibrosis.},
DOI = {10.32604/biocell.2021.011379}
}